Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
CancerVax Inc. expands research to target rare liver cancers with a new immune-boosting platform.
CancerVax Inc. is expanding its preclinical program to include rare forms of liver cancers, HCC, and ICC, using its innovative platform that targets cancer cells without harming healthy ones.
The company's lipid nanoparticles detect cancer cells and mark them for the immune system to destroy.
This expansion adds to their existing work on pancreatic cancer, aiming to address significant unmet needs with a universal treatment approach that could provide off-the-shelf cancer therapies.
4 Articles
CancerVax Inc. amplía la investigación para dirigirse a los cánceres de hígado raros con una nueva plataforma de fortalecimiento inmunológico.